Background. When determining eligibility for isoniazid preventive therapy of human immunodeficiency virus (HIV)-infected patients, the cutoff value of the tuberculin skin test (TST) is often reduced from an induration of 10 mm in diameter to one of 5 mm in diameter to compensate for loss of sensitivity. The effectiveness of this reduction depends on the underlying mechanism: a gradual decrease in skin test responsiveness with decreasing immunocompetence or an all-or-nothing switch to complete anergy. No published studies have assessed this directly in patients with tuberculosis.
The HIV epidemic has strongly increased tuberculosis incidences in sub-Saharan Africa [1] . Isoniazid preventive therapy reduces the risk of tuberculosis among patients coinfected with Mycobacterium tuberculosis and HIV [2] . Isoniazid preventive therapy has been shown to be cost-effective in sub-Saharan Africa [3] and is recommended by the World Health Organization for HIV-infected persons with latent tuberculosis infection (LTBI) [4] . The tuberculin skin test (TST) has high sensitivity and specificity for detecting LTBI, but its sensitivity is reduced for persons with impaired cellmediated immunity, including individuals with HIV infection [5] .
To prevent false-negative results, guidelines for detecting LTBI generally recommend the use of lower cutoff values for a positive TST result for HIV-infected persons (e.g., an induration 5 mm in diameter instead of 10 mm in diameter) [6, 7] . However, this will only be effective if the reduction in sensitivity primarily reflects a lower mean TST response rather than a complete loss of responsiveness [8] . Skin test anergy (i.e., the absence of delayed-type hypersensitivity in sensitized individuals) to tuberculin and other antigens is a well-documented phenomenon among HIV-infected patients and is associated with low CD4 + cell counts [9] [10] [11] . Whether the anergy state is arrived at by a gradual decrease in reaction size or by a mere "switchoff" of the delayed-type hypersensitivity response is less clear. Studies that compared TST responses among HIVinfected and HIV-uninfected persons without tuberculosis yielded contradictory results [12] [13] [14] [15] [16] [17] but were also difficult to interpret, because the true prevalence of LTBI in either group remained unknown. We assessed the sensitivity of the TST among HIV-infected patients by comparing reaction size distributions for HIV-infected and HIV-uninfected patients with bacteriologically confirmed tuberculosis in Tanzania.
PATIENTS AND METHODS
Patients with tuberculosis in Tanzania received TSTs and were tested for HIV infection to obtain a distribution of tuberculin reactions to inform the analysis of the data from the Tanzanian national tuberculin survey [18] . We analyzed these patient data for differences in TST reactions between HIV-infected and HIVnoninfected patients with tuberculosis.
In cross-sectional studies conducted during the period 2000-2003 in 5 referral hospitals (located in Dar es Salaam, Mwanza, Tabora, Kilimanjaro, and Mbeya) and 1 regional hospital (located in Dodoma), all eligible patients present at the time of the study were requested to participate. Eligible patients included all patients admitted to the hospital and outpatients aged у15 years who were receiving treatment for tuberculosis on the basis of at least 2 Ziehl-Neelsen-stained sputum smears with positive results. All patients providing informed consent received TSTs and were tested for HIV infection. TSTs were performed using the Mantoux method with 2TU of RT23 in Tween-80 (Staten Serum Institute), administered with 1-mL disposable syringes and disposable 26-gauge needles on the dorsal side of the left forearm [19] . Skin reactions were read 3 days later as the maximum transverse diameter of the induration and were expressed in millimeters. All tests were administered and read by specially trained staff.
Testing for HIV-1 and HIV-2 antibodies was done at a single laboratory by 2 commercial ELISAs run in parallel (Ezygnost AntiHIV 1&2 Plus [Behring] and Vironostika HIV Uniform II Plus [BioMérieux] ). The test result was considered to be positive when both ELISAs had positive results. Bacille Calmette Guerin (BCG) vaccination status was ascertained from the presence of a typical scar. Sputum grade (i.e., load of bacilli in the sputum smear) was obtained from the laboratory register.
Data were entered in MS Excel 2000 (Microsoft) and were analyzed with MS Excel and Stata software, version 8 (Stata). A total of 100 entered records were randomly selected and checked visually against the raw data; no errors were found.
The distribution of tuberculin reactions 3-28 mm in diameter were smoothed by calculating 5-point moving means to adjust for terminal digit preference (i.e., preference for values of 5, 10, 15, 20 and 25 mm). Sensitivity estimates were based on the smoothed distributions and calculated as the cumulative proportion of patients who had reactions equal to or larger than that value. Anergy was defined as any reaction size of 0, 1, or 2 mm in diameter. Statistical tests of categorical data were performed using x 2 or Fisher's exacts tests as appropriate; distributions were compared by the Student's t test unless stated otherwise. The probability of anergy was assessed in a multivariate logistic regression model; P values were based on the likelihood ratio test. All tests were done at the .05 significance level.
RESULTS
Of 1092 enrolled patients, 79 and 22 patients were excluded because of missing results of the TST and the HIV test, respectively. Of the remaining 991 patients, 451 (45.5%) had test results positive for HIV. The prevalence of HIV infection was higher among women, peaked in the age group 25-34 years old, and varied significantly by hospital but not by diagnostic category, sputum smear grade, or time since the start of tuberculosis treatment (table 1) .
The distribution of crude reaction sizes showed some terminal digit preference that was removed by smoothing. Anergy was observed in 129 (13.0%) of 991 patients, including 18 (3.3%) of 540 HIV-uninfected and 111 (24.6%) of 451 HIVinfected patients. HIV status was a strong predictor of anergy (OR, 9.47; 95% CI, 5.65-15.87;
). This was unaffected P ! .001 by multivariate adjustment for age, sex, hospital, diagnostic category, BCG vaccination status, sputum grade, and time since the start of treatment in a logistic regression model (adjusted OR, 9.60;
). In the model, the only other variables in-P ! .001 dependently associated with anergy were hospital ( ) and P ! .001 time since the start of tuberculosis treatment ( ). P p .043 The smoothed distributions of reaction sizes 12 mm in diameter among HIV-uninfected and HIV-infected patients were similar, with the mode at 17 mm for both groups (figure 1). Distribution means (‫ע‬SD) were lower among HIV-infected patients than among HIV-uninfected patients for both crude distributions ( mm and mm, respectively; 15.9 ‫ע‬ 5.0 16.8 ‫ע‬ 3.8 by Wilcoxon's rank sum test) and smoothed distri-P p .048 butions ( mm and mm, respectively; 15.6 ‫ע‬ 4.8 16.7 ‫ע‬ 3.2 ). Among HIV-infected patients, the proportion of P p .027 reaction sizes of у15 mm in diameter was lower than that among HIV-uninfected patients, whereas the proportion of reaction sizes !10 mm in diameter was higher (table 2) . The difference between HIV-infected and HIV-uninfected individuals with respect to the proportion of reaction sizes 5-9 mm in diameter was 3.6% among all patients ( ) and 5.8% P p .011 among patients with reaction sizes 12 mm in diameter (P ! ). Among patients with reaction sizes 12 mm in diameter, .001 neither the difference in distribution means nor the difference in the proportion of reaction sizes 5-9 mm in diameter were affected by time since the start of tuberculosis treatment (data not shown). The sensitivity of the TST, based on the crude distribution among HIV-uninfected patients at cutoff values of 15, 10, and 5 mm, was 66.7%, 91.1%, and 95.2% (figure 2). Among HIVinfected patients, the sensitivity of the TST for these cutoff values was 45.2%, 64.3%, and 71.2%, respectively. After adjustment for tuberculosis-specific anergy (i.e., after subtracting the 3.3% anergy observed among HIV-uninfected patients), the sensitivity at cutoff values of 15, 10, and 5 mm was 70.0%, 94.4%, and 98.5%, respectively, among HIV-uninfected patients and was 48.5%, 67.6%, and 74.5%, respectively, among HIVinfected patients. Based on the smoothed distributions, the corresponding corrected sensitivity estimates were 67.9%, 94.3%, and 98.5% among HIV uninfected patients and were 48.5%, 65.1%, and 74.5% among HIV-infected patients.
DISCUSSION
We found that the difference in sensitivity of the TST between HIV-infected and HIV-uninfected patients was mainly attributable to a difference in the prevalence of skin test anergy. Among the reactors, there was a statistically significant shift in reaction size distribution towards the lower values for HIVinfected patients, compared with HIV-uninfected patients, but the magnitude of the shift was small. The difference in distribution means among patients with TST reactions was only 1 mm. Although the proportion of anergy was 21% greater among HIV-infected patients than among HIV-uninfected patients, the proportion of reactions 5-9 mm in diameter differed by only 4%. This is reflected in the limited gain in sensitivity as a result of reducing the cutoff value for HIV-infected patients. Although changing the cutoff value from 10 mm to 5 mm increased the sensitivity among HIV-infected patients by 7%, the sensitivity still did not exceed 71%.
These findings suggest that the reduced sensitivity of the TST in patients with HIV infection is primarily attributable to a "switch-off" of TST responsiveness (i.e. an all-or-nothing phenomenon). There may be an additional gradual decrease in reaction size with decreasing CD4 + cell count, but its contribution seems to be limited. Contrary to the findings of other studies of this subject, our study did not involve persons with possible LTBI; instead, it involved patients with tuberculosis who, by definition, have tuberculosis infection. That findings concerning TST responsiveness among HIV-infected patients with tuberculosis can be extrapolated to HIV-infected persons with LTBI is unproven. Distributions of TST reactions in patients with active tuberculosis and LTBI are, however, highly similar, except for the anergy that may occur in patients with cases of severe tuberculosis disease [11, 19, 20] . This loss of responsiveness is antigen-specific and is associated with IL-10-mediated suppression of T cell proliferation [21] . Part of the anergy observed among HIV-infected patients, therefore, is expected to be attributable to the tuberculosis disease, rather than to the HIV infection. This is reflected in the 3.3% anergy observed among the HIV-uninfected patients, a proportion that is well within the 2%-7% range reported by other TST studies involving patients with tuberculosis from the pre-HIV infection era [22] [23] [24] [25] . Therefore, we adjusted the sensitivity estimate among HIV-infected patients for the expected proportion of anergy as observed among the HIV-uninfected patients. Even then, the sensitivity at a cutoff value of 5 mm remained !75%.
Our data have a number of limitations. First, some patientsin particular, those with HIV infection-may have had pulmonary manifestations of nontuberculous mycobacterial infections [26] . Because cross-reactive TST responses occur in .002
a Reactive patients were defined as patients with a TST reaction diameter 12 mm.
these infections-although generally with smaller reaction sizes [27] -these could account for part of the difference in the 5-9-mm group. Second, the TST reaction size distribution displayed some preference for multiples of 5, which results in reading errors around these values [28] . Smoothing by taking a 5-point mean removed most of the potential effects of such reading errors. The sensitivity estimates based on the crude and smoothed distributions, however, showed no relevant differences, indicating that the observed terminal digit preference did not affect the results. Third, the prevalence of anergy to tuberculin has been shown to increase with decreasing CD4 + cell count [10, 12, 29] . It may be, therefore, that the large contribution of anergy, compared with the gradual decline of the TST reaction, reflected relatively low CD4 + cell counts in the patients in our study (i.e., lower than in an unselected population of HIV-infected Tanzanians with LTBI). We were not able to assess this, because no information on CD4 + cell counts was available. However, the prevalence of anergy in our study was at the lower end of the 27%-69% range of anergy prevalence reported from other studies involving HIV-infected patients with tuberculosis in sub-Saharan Africa [29] [30] [31] [32] . Moreover, studies of anergy panel testing among HIV-infected persons without tuberculosis showed a higher prevalence of anergy (30%-49%) than was found in our study [12, 14, 33, 34] , even when restricted to those with CD4 + cell counts 1 cells/L (28%-44%) [12, 33] . This sug-9 350 ϫ 10 gests that the prevalence of anergy found in our study did not substantially overestimate the prevalence expected among HIVinfected patients with LTBI.
By reducing the cutoff value for a positive TST result among HIV-infected patients from 10 mm to 5 mm, 7% more cases of LTBI would be detected. The associated increase in negative predictive value (or a reduction of the proportion of falsenegative test results), as such, is worth attaining. However, this increase in negative predictive value may come at the cost of a substantial decrease in positive predictive value (or an increase in the proportion of false-positive test results). This will be the case if the specificity of the TST or the prevalence of LTBI in the population tested is low [35] . Low specificity of the TST is expected in populations with high coverage of BCG vaccination or a high prevalence of cross-reactive nontuberculous mycobacterial infections [5] . In sub-Saharan Africa, TST responses to nontuberculous mycobacteria are frequent [18, 36] . Specificity estimates can be obtained from the distribution of TST reactions in a tuberculin survey, assuming that reactions among infected children are normally distributed around a mean value of 17 mm and that all values of у17 mm represent LTBI [35, 37] . Data from the third Tanzanian national tuberculin survey, performed during 1993-1998, suggest that, in Tanzania, the specificity of the TST with 2TU RT23 among school children without BCG vaccination was ∼95% at a cutoff value of 10 mm, but only ∼85% at a cutoff value of 5 mm [38] . In countries with low prevalence, the positive predictive value at a cutoff level of 5 mm may be low, even in the presence of low to moderate prevalence of nontuberculous mycobacterial infections. For example, in The Netherlands, the estimated positive predictive value among nonvaccinated adults of the TST with 2TU RT23 at this cutoff level is 70% with a 10% prevalence of LTBI, and it is only 39% with a 3% prevalence of LTBI [35] . A similarly low positive predictive value can be expected in the United States, where LTBI prevalence is generally low and where cross-reactive TST responses occur [27] . There are no data on the effect of HIV infection on crossreactive TST responses to BCG vaccination or nontuberculous mycobacterial infection. Therefore, it is unclear to what extent these estimates can be extrapolated to HIV-infected patients who are tested for LTBI. Nonetheless, a potential consequence of using 5 mm instead of 10 mm as the cutoff value for a positive TST result among HIV-infected patients in these circumstances is that a limited reduction in false-negative TST results is offset by a much larger increase in false-positive TST results. This could result in unnecessary prophylactic treatment of HIV-infected persons, with associated costs in terms of severe adverse effects and increased health service workload. An added disadvantage of using different cutoff values for testing HIVinfected and HIV-uninfected persons may be confusion and the potential loss of subject confidentiality. It is important that these considerations are taken into account when guidelines for detection of LTBI among HIV-infected patients are developed. Our findings may also be a reason to reconsider existing guidelines, such as that issued by the US Centers for Disease Control and Prevention [6] .
We conclude that the reduction in sensitivity of the TST is predominantly caused by anergy that occurs as an all-or-nothing phenomenon. Consequently, the gain in sensitivity and in negative predictive value of reducing the cutoff value for a positive TST result from 10 mm to 5 mm is limited.
